- Home
- LRMR vs BGX Comparison
LRMR vs BGX Comparison
Compare LRMR & BGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LRMR
- BGX
- Stock Information
- Founded
- LRMR N/A
- BGX 2010
- Country
- LRMR United States
- BGX United States
- Employees
- LRMR N/A
- BGX N/A
- Industry
- LRMR Biotechnology: Pharmaceutical Preparations
- BGX Trusts Except Educational Religious and Charitable
- Sector
- LRMR Health Care
- BGX Finance
- Exchange
- LRMR Nasdaq
- BGX Nasdaq
- Market Cap
- LRMR 183.8M
- BGX 150.8M
- IPO Year
- LRMR N/A
- BGX N/A
- Fundamental
- Price
- LRMR $2.12
- BGX $12.16
- Analyst Decision
- LRMR Strong Buy
- BGX
- Analyst Count
- LRMR 9
- BGX 0
- Target Price
- LRMR $19.00
- BGX N/A
- AVG Volume (30 Days)
- LRMR 1.4M
- BGX 67.9K
- Earning Date
- LRMR 04-30-2025
- BGX 01-01-0001
- Dividend Yield
- LRMR N/A
- BGX 10.34%
- EPS Growth
- LRMR N/A
- BGX N/A
- EPS
- LRMR N/A
- BGX N/A
- Revenue
- LRMR N/A
- BGX N/A
- Revenue This Year
- LRMR N/A
- BGX N/A
- Revenue Next Year
- LRMR N/A
- BGX N/A
- P/E Ratio
- LRMR N/A
- BGX N/A
- Revenue Growth
- LRMR N/A
- BGX N/A
- 52 Week Low
- LRMR $1.61
- BGX $10.69
- 52 Week High
- LRMR $11.20
- BGX $12.44
- Technical
- Relative Strength Index (RSI)
- LRMR 44.72
- BGX 55.00
- Support Level
- LRMR $2.03
- BGX $11.74
- Resistance Level
- LRMR $2.33
- BGX $12.23
- Average True Range (ATR)
- LRMR 0.30
- BGX 0.15
- MACD
- LRMR -0.01
- BGX 0.04
- Stochastic Oscillator
- LRMR 11.21
- BGX 85.71
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
About BGX Blackstone Long Short Credit Income Fund
Blackstone Long-Short Credit Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income, with a secondary objective to seek preservation of capital, consistent with its primary goal of high current income. It seeks to achieve its investment objectives by employing a dynamic long-short strategy in a diversified portfolio of loans and fixed-income instruments of predominantly U.S. corporate issuers, including first- and second-lien secured loans (Secured Loans) and high-yield corporate bonds of varying maturities.